Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease,Mild Cognitive Impairment,and Healthy Controls

Abstract

Amyloid load in the brain using Pittsburgh compound B (¹¹C-PIB) positron emission tomography (PET) and cerebral glucose metabolism using fluorodeoxyglucose (¹⁸F-FDG) PET were evaluated in patients with mild Alzheimer disease (AD, n = 18), mild cognitive impairment (MCI, n = 24), and controls (CTR, n = 18). ¹¹C-PIB binding potential (BP_ND) was higher in prefrontal cortex, cingulate, parietal cortex, and precuneus in AD compared to CTR or MCI and in prefrontal cortex for MCI compared to CTR. For ¹⁸F-FDG, regional cerebral metabolic rate for glucose (rCMRGlu) was decreased in precuneus and parietal cortex in AD compared to CTR and MCI, with no MCI—CTR differences. For the AD—CTR comparison, precuneus BP_ND area under the receiver operating characteristic (ROC) curve (AUC) was 0.938 and parietal cortex rCMRGlu AUC was 0.915; for the combination, AUC was 0.989. ¹¹C-PIB PET BP_ND clearly distinguished diagnostic groups and combined with ¹⁸F-FDG PET rCMRGlu, this effect was stronger. These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies.

Keywords

Alzheimer disease mild cognitive impairment PET scan Pittsburgh compound B FDG

Get full access to this article

View all access options for this article.

References

Minino AM , Heron MP , Murphy SL , et al. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System Deaths: final data for 2004. . Natl Vital Stat Rep. 2007;55(19):1-119.

Knopman DS , DeKosky ST , Cummings JL , et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.

Klunk WE , Engler H. , Nordberg A. , et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.

Hyman BT , West HL , Rebeck GW , et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A. 1995;92(8):3586-3590.

Price JL , Morris JC Tangles and plaques in nondemented aging and ‘‘preclinical’’ Alzheimer’s disease. Ann Neurol. 1999 ;45(3): 358-368.

Mathis CA , Lopresti BJ , Klunk WE Impact of amyloid imaging on drug development in Alzheimer’s disease . Nucl Med Biol. 2007;34(7):809-822.

Bacskai BJ , Frosch MP , Freeman SH , et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434.

Ikonomovic MD , Klunk WE , Abrahamson EE , et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131(pt 6):1630-1645.

Rowe CC , Ng S. , Ackermann U. , et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.

10.

Mintun MA , Larossa GN , Sheline YI , et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.

11.

Ng S. , Villemagne VL , Berlangieri S. , et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48(4):547-552.

12.

Mikhno A. , Devanand D. , Pelton G. , et al. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer’s disease. J Nucl Med. 2008;49(8):1262-1269.

13.

Aizenstein HJ , Nebes RD , Saxton JA , et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol . 2008;65(11):1509-1517.

14.

Villemagne VL , Pike KE , Darby D. , et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia. 2008;46(6): 1688-1697.

15.

Forsberg A. , Engler H. , Almkvist O. , et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.

16.

Jack CR Jr , Lowe VJ , Senjem ML , et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680.

17.

Kemppainen NM , Aalto S. , Wilson IA , et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68(19):1603-1606.

18.

Wolk DA , Price JC , Saxton JA , et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557-568.

19.

Okello A. , Koivunen J. , Edison P. , et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009 ;73(10):754-760.

20.

Silverman DH , Small GW , Chang CY , et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120-2127.

21.

Mosconi L. , Tsui WH , Herholz K. , et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390-398.

22.

Chételat G. , Desgranges B. , de la Sayette V. , et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003;60(8):1374-1377.

23.

Drzezga A. , Lautenschlager N. , Siebner H. , et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(8):1104-1113.

24.

Li Y. , Rinne JO , Mosconi L. , et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008; 35(12):2169-2181.

25.

Ziolko SK , Weissfeld LA , Klunk WE , et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer’s disease. Neuroimage. 2006; 33(1):94-102.

26.

Rabinovici GD , Furst AJ , O’Neil JP , et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205-1212.

27.

Edison P. , Archer HA , Hinz R. , et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501-508.

28.

Kadir A. , Andreasen N. , Almkvist O. , et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer’s disease. Ann Neurol. 2008;63(5):621-631.

29.

Drzezga A. , Grimmer T. , Henriksen G. , et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage . 2008;39(2):619-633.

30.

Jagust WJ , Landau SM , Shaw LM , et al. Alzheimer’s Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.

31.

Lowe VJ , Kemp BJ , Jack CR Jr , et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009; 50(6):878-886.

32.

McKhann G. , Drachman D. , Folstein M. , Katzman R. , Price D. , Stadlan EM Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.

33.

Petersen RC , Smith GE , Waring SC , Ivnik RJ , Tangalos EG , Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.

34.

Parsey RV , Sokol LO , Bélanger MJ , et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun. 2005;26(10):875-880.

35.

Watson CC , Newport D. , Casey ME A single scatter simulation technique for scatter correction in 3D PET. In: Grangeat P , Amans J-L , eds. Three Dimensional Image reconstruction in Radiology and Medicine. Dordrecht, The Netherlands: Kluwer Academic; 1996:255-268.

36.

Mawlawi O. , Martinez D. , Slifstein M. , et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab . 2001;21(9):1034-1057.

37.

Deloar HM , Fujiwara T. , Shidahara M. , et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging . Eur J Nucl Med. 1998;25(6):565-574.

38.

Duvernoy H. The Human Brain. Surface, Three-Dimensional Sectional Anatomy and MRI. New York: Sringer- Verlag Wien; 1991.

39.

Ogden RT , Ojha A. , Erlandsson K. , Oquendo MA , Mann JJ , Parsey RV In vivo quantification of serotonin transporters using [(11)C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab. 2007; 27(1):205-217.

40.

Devanand DP , Pradhaban G. , Liu X. , et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007;68(11):828-836.

41.

Joachim CL , Morris JH , Selkoe DJ Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol. 1989;135(2):309-319.

42.

Logan J. , Fowler JS , Volkow ND , Wang GJ , Ding YS , Alexoff DL Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996 ;16(5):834-840.

43.

Price JC , Klunk WE , Lopresti BJ , et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547.

44.

Lopresti BJ , Klunk WE , Mathis CA , et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.

45.

Phelps ME , Huang SC , Hoffman EJ , Selin C. , Sokoloff L. , Kuhl DE Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6(5):371-388.

46.

Raji CA , Becker JT , Tsopelas ND , et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer’s disease with Pittsburgh compound B. J Neurosci Methods. 2008;172(2):277-282.

47.

Engler H. , Forsberg A. , Almkvist O. , et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 2006;129(pt 11):2856-2866.

48.

Pike KE , Savage G. , Villemagne VL , et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain . 2007;130(pt 11): 2837-2844.

49.

Mormino EC , Kluth JT , Madison CM , et al. Alzheimer’s Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.

50.

Drzezga A. , Grimmer T. , Henriksen G. , et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009 ;72(17):1487-1494.

51.

Reiman EM , Chen K. , Liu X. , Bandy D. , et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009; 106(16):6820-6825.